71P - Investigating molecular biomarkers in SCLC

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Small-Cell Lung Cancer
Translational Research
Presenter Fatma Abdelraouf
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors F. Abdelraouf1, D. Gonzalez de Castro2, A. Wotherspoon3, M. Maurya2, D. Mair2, J. Bhosle4, S. Popat4, M. O'Brien5
  • 1Departments Of Medicine And Clinical Pathology, The Royal Marsden NHS Foundation Trust and Cairo University, SM2 5PT - Surrey/UK
  • 2Department Of Molecular Diagnostics, The Royal Marsden NHS foundation Trust, The Institute of Cancer Research, Surrey/UK
  • 3Department Of Histopathology, The Royal Marsden Hospital NHS Foundation Trust, Surrey/UK
  • 4Department Of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Surrey/UK
  • 5Department Of Medicine, The Royal Marsden Hospital NHS Foundation Trust, SM2 5PT - Surrey/UK

Abstract

Small cell lung cancer (SCLC) is an aggressive cancer that relapses quickly after conventional treatment. Molecular biomarkers have been investigated in non-small cell lung cancer (NSCLC) and targeted treatments in advanced disease are established. Currently there are no established targeted therapies in SCLC and the aim of this study was to examine for the presence of known molecular targets in patients with SCLC.